OR WAIT null SECS
August 15, 2022
Genentech has updated the warnings section of the label for the MS therapy Ocrevus to include information about cases of immune-mediated colitis and a serious brain infection in the post-marketing setting.
July 28, 2022
Kelly Stanton, director of quality at Qualio, talks about the impact on patients of prescription drug recalls.
July 27, 2022
This follows a move by Bayer to import Ultravist with non-U.S. labeling also to address pandemic-related shortages of iodine-containing contrast media used in imaging procedures.
July 18, 2022
BMS warns about the risk of extramedullary hematopoiesis, a rare complication in which the production of blood cells occurs outside of the bone marrow.
July 14, 2022
Particulates were seen in a single vial, which could lead to blockage of blood vessels, including decreased blood flow to the brain, heart attack, and pulmonary embolus.
July 07, 2022
This is the second batch to be recalled because of the potential of missing labels.
July 01, 2022
Final results from a phase 3 study found that Copiktra was associated with a higher risk of serious side effects, dose modifications, and deaths compared with Kesimpta.
June 27, 2022
Labels now warn that buprenorphine products that dissolve in the mouth can cause dental problems. Buprenorphine is used to treat opioid use disorder and pain.
June 24, 2022
Byetta is used to control blood sugar in patients with diabetes. A new warning includes the risk of gallstones and gallbladder inflammation.
June 09, 2022
The recalls were made because the medications failed sterility testing.
